BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

BioNTech SENASDAQ: BNTX

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense remains negative

Q2 FY2026 income tax expense was -€37.9M, compared with -€16.1M a year earlier. Trailing-twelve-month income tax expense was €55.58M. Over 3 fiscal years it compounded at -71.4% a year.

Context

  • Income tax expense amounted to 3.0% of revenue in FY2025, up 2.5 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income tax expense holds near -€37.9M or moves back toward the trailing-twelve-month quarterly average of €13.89M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-€37.9M-3.0% QoQ
Last fiscal yearDec 2025
€81.93M+760.8% YoY
LTMJun 2026
€55.58M+228.1% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-135.4%——
1 year+760.8%——
3-year CAGR-71.4%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

EUR · from the income statement

Latest · FY2025
81.93M EUR
Year-over-year change
+760.8%
4-year CAGR
-63.8%

Income Tax Expense vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +228.1% is the 2nd highest of 9, against a peer median of -43.6%.
  • Income tax expense amounts to 2.1% of revenue for BNTX, versus a peer median of 2.4%.
BNTX Competitors
Income Tax Expense for BNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$354.98M USD-9.3%+26.1%6.1%
GMABGenmab A/SLTM Jun 2026$118.01M USD—-45.5%2.9%
BNTXBioNTech SELTM Jun 2026€55.58M EUR+228.1%-71.4%2.1%
TGTXTG Therapeutics, Inc.LTM Sep 2026$43.49M USD+112.1%—4.8%
IMCRImmunocore Holdings plcLTM Mar 2026$11M USD+1059.7%+8.2%2.9%
XNCRXencor, Inc.LTM Jun 2026$2.48M USD+53.2%+55.0%2.4%
CGENCompugen Ltd.LTM Mar 2026$28K USD-99.4%-2.4%0.0%
IBRXImmunityBio, Inc.LTM Sep 2026-$144K USD——0.1%
MGNXMacroGenics, Inc.LTM Mar 2026-$672K USD-171.2%—0.4%
IMTXImmatics N.V.LTM Mar 2026-€942K EUR-124.8%—2.5%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$1.24M USD-77.9%—0.3%
Peer median (excluding BNTX) —-43.6%+8.2%2.4%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.98B17.31B3.82B2.75B2.76B
Cost of Revenue2.91B3B599.8M541.3M616.47M
Gross Profit16.07B14.32B3.22B2.21B2.14B
Gross Margin84.7%82.7%84.3%80.3%77.6%
Research & Development949.2M1.54B1.78B2.25B2.02B
Selling, General & Admin327.2M541.2M557.7M599M698.2M
Operating Expenses781.4M1.67B2.53B3.52B2.76B
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
EBITDA15B13.1B1.38B(367.1M)(628M)
EBITDA Margin79.1%75.7%36.1%-13.3%-22.8%
Operating Income15.28B12.64B690.4M(1.31B)(623.87M)
Operating Margin80.5%73.0%18.1%-47.8%-22.6%
Interest Income1.56M47.37M351.31M0252.24M
Interest Expense5.63M15.82M7.76M13.16M13.64M
Other Income / Expenses(237.4M)311.4M495.7M636.6M(385.46M)
Income Before Tax15.05B12.95B1.19B(677.7M)(1.01B)
Pre-Tax Margin79.3%74.8%31.1%-24.6%-36.6%
Income Tax Expense4.75B3.52B255.8M(12.4M)81.93M
Net Income10.29B9.43B930.3M(665.3M)(1.09B)
Net Margin54.2%54.5%24.4%-24.2%-39.6%
EPS (Basic)43.8738.083.87(2.77)(4.51)
EPS (Diluted)41.2137.093.83(2.77)(4.51)
Weighted Avg Shares244M243.3M240.6M240.4M241.7M
Weighted Avg Shares (Diluted)259.7M249.8M242.7M240.4M241.7M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.